MSLN and hematologic disorder: The most recent developments include CAR-T cell engineering for alternative targets such as the granulocyte-macrophage colony-stimulating factor receptor (hGMR or CD116) for hematological malignancies [209], the epidermal growth factor receptor (EGFR) as a target for non-small-cell lung carcinoma [210], glypican-3 and EGFRvIII targeting hepatocellular carcinoma [211,212] and membrane-proximal mesothelin (MSLN) epitope-targeting against MSLN-positive solid tumors [213].